Vivus Inc (VVUS)
$0.47 0.00 (0.00%)
19:59 EDT VVUS Stock Quote Delayed 30 Minutes
Previous Close -
Market Cap 49.47M
PE Ratio -1.23
Volume (Avg. Vol.)
Day's Range 0.47 - 0.47
52-Week Range 0.44 - 4.55
Dividend & Yield N/A (N/A)
VVUS Stock Predictions, Articles, and Vivus Inc News
- From InvestorPlace
- From the Web
We take a look at three biotech stocks whose share price has increased in the past month due to as the biotech industry bounced back in the past month after dec....
The Food and Drug Administration (FDA) announced a list of drug makers that have tried to block generic drugs in its new shame list. Here they are.
VIVUS is a biopharmaceutical company developing and commercializing innovative, next-generation therapies. Here's why VVUS stock is a must
This week, the ratings of 17 Pharmaceuticals stocks on Portfolio Grader are down. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
The ratings of 13 Pharmaceuticals stocks are down this week, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
This week, 12 Pharmaceuticals stocks are worse, according to the Portfolio Graderdatabase. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
Surprise! Vivus stock has been one of the market's hottest names since September. Maybe we should trust the guy making it happen.
Envivio, Vivus, Medovex, One Group Hospitality and VolitionRX were among a number of cheap stocks that charged significantly higher this week.
Orexigen's Contrave joined a couple other FDA-approved weight-loss treatments on the market ... and the OREX product is a serious player.
Ten years' worth of work from Mannkind Corporation on Afrezza has just been validated, but that doesn't automatically make the stock a good bet right here, and right now.
VIVUS stock (VVUS) has taken a hit following a downgrade by equities research analysts at Piper Jaffray.
This week, the overall grades of three pharmaceutical stocks are lower, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").